1. Spain Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Grifols, S.A.

Grifols, S.A.

GIKLY
Grifols, S.A.US flagOther OTC
5.10
USD
- -
- -
13.40BMarket Cap
Grifols, S.A.
GIKLY
(Other OTC)

Recent

price

5.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.91
2.91
1.91
2.01
2.45
2.87
2.96
3.16
3.28
3.72
3.89
3.62
4.46
4.85
5.31
5.53
5.46
Revenue per Share
0.22
0.08
0.19
0.25
0.34
0.39
0.4
0.48
0.44
0.46
0.45
0.14
0.14
0.03
0.12
0.3
0.22
Basic EPS, GAAP
- -
0.1
0.25
0.31
0.5
0.13
0.19
0.38
0.31
0.11
0.55
0.21
-0.29
-0.07
0.39
0.46
0.7
Free Cash Flow per Basic Share
0.05
- -
- -
0.05
0.11
0.16
0.16
0.16
0.2
0.17
0.08
0.19
- -
- -
- -
0.09
- -
Dividend per Share
0.43
0.27
0.27
0.29
0.37
0.39
0.4
0.48
0.42
0.44
0.54
0.23
0.09
0.12
0.2
0.31
0.22
Book Value per Share
0.85
-2.01
-0.7
-0.49
-1.15
-1.02
-0.81
-1.63
-1.39
-0.07
-0.12
-0.4
-1.46
-1.56
-1.27
-1.44
-1.47
Tangible Book Value per Share
518
616
1,371
1,362
1,371
1,371
1,366
1,368
1,369
1,370
1,371
1,363
1,360
1,360
1,359
1,361
1,365
Basic Weighted Avg Shares
991
1,796
2,621
2,742
3,355
3,935
4,050
4,318
4,487
5,099
5,340
4,933
6,064
6,592
7,212
7,524
7,446
Sales/Revenue/Turnover
21.16
15.53
25.18
26.85
25.56
24.66
23.2
23.24
22.16
22.01
18.26
11.4
11.2
10.89
16.01
16.63
17.8
Operating Margin (%)
46
91
129
128
189
190
202
215
229
302
322
360
411
446
438
450
437
Depreciation Expense
116
50
257
346
470
532
545
663
597
625
619
189
185
42
157
402
298
Net Income, GAAP
26.95
37.23
34.17
31.25
20.79
23.01
23.6
4.95
18.11
20.62
19.31
24.29
26.66
20.87
52.03
18.7
37.66
Effective Tax Rate (%)
11.66
2.8
9.79
12.6
14.01
13.52
13.47
15.35
13.3
12.26
11.58
3.83
3.05
0.64
2.18
5.34
4
Profit Margin (%)
721
1,283
1,342
1,424
1,833
2,036
2,051
1,967
2,226
3,996
1,830
2,036
2,671
3,806
3,572
3,055
3,256
Working Capital
665
2,809
2,586
2,438
4,072
4,572
4,681
5,878
6,021
6,786
6,592
6,930
9,069
9,985
9,445
9,043
8,425
LT Debt
707
1,665
1,881
2,107
2,663
3,301
3,728
3,634
4,697
6,846
6,720
7,317
7,976
7,514
8,606
7,603
7,598
Total Equity
10.32
5.64
9.35
10.7
11.52
9.9
8.58
10.42
7.99
7.22
5.7
2.81
2.9
3.14
2.97
5.65
5.48
Return on Invested Capital (%)
13.3
7.46
13.64
15.91
16.19
14.06
13.44
14.89
11.97
10.22
7.45
2.8
3.79
2.58
2.95
6.07
4.03
Return on Capital (%)
62.44
25.78
94.59
89.64
104.46
102.73
101.55
110.31
96.32
105.29
91.9
36.07
86.48
29.84
71.54
115.35
57.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
ST Debt
900
- -
394
LT Borrowings
5,968
- -
7,448
LT Finance Leases
738
- -
978
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
679
- -
680
Market Capitalization
15,989
6,509
7,108

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Mar'25
Jun'25
Total Current Assets
3,240
- -
5,246
Cash, Cash Equivalents & STI
408
- -
566
Accounts Receivable, Net
532
- -
749
Inventories
2,124
- -
3,347
Total Current Liabilities
1,921
- -
1,990
Payables & Accruals
787
- -
1,181
ST Debt
900
- -
394
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.85%
3%
-11.65%
Free Cash Flow
-58.67%
-206.15%
17.74%
Net Income, GAAP
29.89%
56.22%
156.05%
Sales/Revenue/Turnover
6.96%
7.55%
4.33%
Total Cash Common Dividend
- -
- -
12,700%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,818
1,793
1,976
- -
7,212
2025
1,786
1,891
1,982
- -
7,524
2026
1,700
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.04
0.05
- -
0.12
2025
0.04
0.08
- -
- -
0.3
2026
0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.09
2026
- -
- -
- -
- -
- -
Similar Companies
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Novartis AG (NVS)
Haw Par Corporation Limited (HAWPY)
Roche Holding AG (RHHBY)
Otsuka Holdings Co., Ltd. (OTSKY)
Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ)
Business
Grifols, S.A. (GIKLY) is a global healthcare company and leading producer of plasma-derived medicines that develops, manufactures and markets protein therapies for patients with rare and chronic diseases, including immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors; diagnostic solutions for transfusion medicine such as blood typing reagents, instruments and software; biological supplies for life-science research and clinical trials; and hospital products encompassing intravenous solutions, clinical nutrition and medical devices. The company operates through three primary divisions—Bioscience, Diagnostics and Hospital—serving therapeutic areas including immunology, infectious diseases, pulmonology, neurology, hepatology, hematology and intensive care, with products distributed to hospitals, pharmacies, blood banks and healthcare professionals in over 110 countries. Founded in 1909 and headquartered in Sant Cugat del Vallès, Barcelona, Spain, Grifols maintains the world's largest private network of approximately 400 plasma collection centers across North America, Europe, Africa, the Middle East and China via its partnership with Shanghai RAAS. In recent developments, Grifols announces plans in mid-2025 to construct a new manufacturing facility in Spain to double its plasma fractionation capacity in Europe as part of its Value Creation Plan, supporting 7% revenue growth to EUR 3,677 million and net profit of EUR 177 million in the first half of 2025; completes the delisting of Biotest in June 2025 following its 2022 acquisition to expand plasma therapies and European operations; concludes in December 2024 a balance sheet improvement process through a EUR 1.3 billion private placement of senior secured notes and revolving credit facility extension, backed by global investors; finalizes in June 2024 the sale of a 20% equity stake in Shanghai RAAS to Haier Group for approximately USD 1.8 billion, establishing a strategic alliance; secures investor approval in November 2025 for amendments to its EUR 1.3 billion secured notes and receives positive credit rating actions from Fitch and Moody's; and undergoes governance changes including the appointment of Anne-Catherine Berner as Chair in June 2025, Rahul Srinivasan as CFO in July 2024 and Nacho Abia as CEO in April 2024.

Company News

APIChatGPT

  • seekingalpha.com

    Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

  • globenewswire.com

    Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

  • seekingalpha.com

    Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript